Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Eosinophilic Esophagitis-Pipeline Review, H1 2015

Eosinophilic Esophagitis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Eosinophilic Esophagitis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Eosinophilic Esophagitis-Pipeline Review, H1 2015', provides an overview of the Eosinophilic Esophagitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Eosinophilic Esophagitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Eosinophilic Esophagitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Eosinophilic Esophagitis Overview 7

Therapeutics Development 8

Pipeline Products for Eosinophilic Esophagitis-Overview 8

Pipeline Products for Eosinophilic Esophagitis-Comparative Analysis 9

Eosinophilic Esophagitis-Therapeutics under Development by Companies 10

Eosinophilic Esophagitis-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Eosinophilic Esophagitis-Products under Development by Companies 14

Eosinophilic Esophagitis-Companies Involved in Therapeutics Development 15

Actavis plc 15

DBV Technologies S.A. 16

Dr. Falk Pharma GmbH 17

Lipella Pharmaceuticals, Inc. 18

Novartis AG 19

Oxagen Limited 20

Receptos, Inc. 21

Regeneron Pharmaceuticals, Inc. 22

Shire Plc 23

Teva Pharmaceutical Industries Limited 24

Eosinophilic Esophagitis-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

Allergen for Milk Allergy-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

budesonide-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

budesonide-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

dupilumab-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

EUR-1100-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

OC-459-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

QAX-576-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

reslizumab-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

RPC-4046-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

tacrolimus liposomal-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Eosinophilic Esophagitis-Recent Pipeline Updates 50

Eosinophilic Esophagitis-Dormant Projects 58

Eosinophilic Esophagitis-Product Development Milestones 59

Featured News & Press Releases 59

Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 59

Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 59

Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 60

May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 61

Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 62

May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 62

May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 63

Nov 23, 2009: Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 64

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H1 2015 8

Number of Products under Development for Eosinophilic Esophagitis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Eosinophilic Esophagitis-Pipeline by Actavis plc, H1 2015 15

Eosinophilic Esophagitis-Pipeline by DBV Technologies S.A., H1 2015 16

Eosinophilic Esophagitis-Pipeline by Dr. Falk Pharma GmbH, H1 2015 17

Eosinophilic Esophagitis-Pipeline by Lipella Pharmaceuticals, Inc., H1 2015 18

Eosinophilic Esophagitis-Pipeline by Novartis AG, H1 2015 19

Eosinophilic Esophagitis-Pipeline by Oxagen Limited, H1 2015 20

Eosinophilic Esophagitis-Pipeline by Receptos, Inc., H1 2015 21

Eosinophilic Esophagitis-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 22

Eosinophilic Esophagitis-Pipeline by Shire Plc, H1 2015 23

Eosinophilic Esophagitis-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 27

Number of Products by Stage and Mechanism of Action, H1 2015 29

Number of Products by Stage and Route of Administration, H1 2015 31

Number of Products by Stage and Molecule Type, H1 2015 33

Eosinophilic Esophagitis Therapeutics-Recent Pipeline Updates, H1 2015 50

Eosinophilic Esophagitis-Dormant Projects, H1 2015 58

List of Figures

Number of Products under Development for Eosinophilic Esophagitis, H1 2015 8

Number of Products under Development for Eosinophilic Esophagitis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 26

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 30

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31

Number of Products by Top 10 Molecule Types, H1 2015 32

Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actavis plc

DBV Technologies S.A.

Dr. Falk Pharma GmbH

Lipella Pharmaceuticals, Inc.

Novartis AG

Oxagen Limited

Receptos, Inc.

Regeneron Pharmaceuticals, Inc.

Shire Plc

Teva Pharmaceutical Industries Limited

Eosinophilic Esophagitis Therapeutic Products under Development, Key Players in Eosinophilic Esophagitis Therapeutics, Eosinophilic Esophagitis Pipeline Overview, Eosinophilic Esophagitis Pipeline, Eosinophilic Esophagitis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com